Surge Therapeutics Raises $32M Series B Financing To Advance Intraoperative Immunotherapy To Improve Cancer Patient Survival Outcomes Post-Surgery
Amount Raised
$32 Million
Round Type
Series B
CambridgeBiotechnologyHealth CareTherapeuticsInvestors
Description
SURGE Therapeutics (SURGE), a biotech company pioneering the delivery of immunotherapy during cancer surgery, announced today the completion of a $32 million Series B financing led by Bioluminescence Ventures, with participation from KdT Ventures, Piedmont Capital, and existing investors 8VC, Alumni Ventures, Camford Capital, Cancer Research Institute, Intuitive Ventures, Khosla Ventures, and Pitango HealthTech.
Quick answer
SURGE Therapeutics raised $32 Million in a Series B round, dated July 19, 2023. Investors: Pitango Health Tech, Khosla Ventures, Intuitive Ventures, Cancer Research Institute, Camford Capital, Alumni Ventures, 8VC and Piedmont Capital. SURGE Therapeutics is based in Cambridge, Maryland, United States.
- How much did SURGE Therapeutics raise?
- SURGE Therapeutics raised $32 Million in a Series B round on July 19, 2023.
- Who invested in SURGE Therapeutics?
- Pitango Health Tech, Khosla Ventures, Intuitive Ventures, Cancer Research Institute, Camford Capital, Alumni Ventures, 8VC and Piedmont Capital are named as investors in this round.
- What does SURGE Therapeutics do?
- SURGE seeks to dramatically improve cancer patient survival by disrupting how, when, and where cancer immunotherapy is deployed -- focusing 100% of the effective dose at the right place and at the right time.
- Where is SURGE Therapeutics based and how big is it?
- SURGE Therapeutics is based in Cambridge, Maryland, United States.
- Who are the decision-makers at SURGE Therapeutics?
- Fundz holds 1 contact at SURGE Therapeutics, including the CEO. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as SURGE Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Innovac Therapeutics raised $18M (Funding Round) on September 1, 2023.
- Alpha Cognition raised $1.3M (Seed) on August 31, 2023.
- Lexeo Therapeutics raised an undisclosed amount (Corporate Round) on August 28, 2023.
- Rapport raised $150M (Series B) on August 24, 2023.
- Fore Biotherapeutics raised $75M (Series D) on August 24, 2023.
- Actimed Therapeutics raised $6.1M (Series A) on August 22, 2023.
Who to call at SURGE Therapeutics, and when
A new round usually means SURGE Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day SURGE Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at SURGE Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at SURGE Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment SURGE Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansSURGE Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.